Reported 1 day ago
As Denmark's Novo Nordisk looks to replace CEO Lars Fruergaard Jorgensen, analysts suggest the company should seek a leader from the U.S., its largest market. With Novo facing increased competition from U.S. rival Eli Lilly in the obesity drug sector, particularly with disparities in sales of their respective medications, having a CEO familiar with the U.S. pharmaceutical landscape could be advantageous. Historically, Novo has had only Danish CEOs, marking a potential shift in company strategy if they choose to appoint an external candidate.
Source: YAHOO